Analyzing Selectivity Through Multi-dimensional Activity Cliff Analysis

by Thanos Panagiotidis | Mar 27, 2015 | Drug Discovery Applications, Publications and presentations

Analyzing Selectivity Through Multi-dimensional Activity Cliff Analysis Dr Tim Cheeseright, Cresset, gave this presentation at the “Guiding Optimal Compound Design and Development Symposium” held in Cambridge, MA, USA on 19 March 2015. AbstractDuring lead...

Understanding Compound Quality

by Thanos Panagiotidis | Mar 27, 2015 | Drug Discovery Applications, Publications and presentations

Understanding Compound Quality Dr Paul Leeson, Paul Leeson Consulting Ltd, gave this presentation at the “Guiding Optimal Compound Design and Development Symposium” held in Cambridge, MA, USA on 19 March 2015. AbstractA significant body of data suggests...

Predicting Adverse Drug Reactions: What Works and What Doesn’t

by Thanos Panagiotidis | Mar 27, 2015 | Drug Discovery Applications, Publications and presentations

Predicting Adverse Drug Reactions: What Works and What Doesn’t Dr Nigel Green, Pfizer, gave this presentation at the “Guiding Optimal Compound Design and Development Symposium” held in Cambridge, MA, USA on 19 March 2015. AbstractThe ability to predict the...

Modeling of Chemical and Physical Stability of Pharmaceuticals

by Thanos Panagiotidis | Mar 27, 2015 | In Silico Modelling, Publications and presentations

Modeling of Chemical and Physical Stability of Pharmaceuticals Dr Yuriy Abramov, Pfizer, gave this presentation at the “Guiding Optimal Compound Design and Development Symposium” held in Cambridge, MA, USA on 19 March 2015. AbstractOne of the major...

Predicting Metabolites – Enhancing an Expert System with Machine Learning

by Thanos Panagiotidis | Mar 27, 2015 | In Silico Modelling, Publications and presentations

Predicting Metabolites – Enhancing an Expert System with Machine Learning Dr Christopher Barber, Lhasa Limited, gave this presentation at the “Guiding Optimal Compound Design and Development Symposium” held in Cambridge, MA, USA on 19 March 2015....
« Older Entries

Recent Posts

  • Optibrium appoints Steve Yemm as Chief Commercial Officer
  • Introduction to StarDrop™
  • Real world case studies: Predicting pharmacokinetics from limited ADME data with deep learning
  • Inspyra™– Introduction
  • Cerella™– Introduction

Archives

Categories

  • Asteris
  • Cerella
  • Downloads
  • Drug Discovery Applications
  • Events
  • Example Code
  • General
  • In Silico Modelling
  • Latest Videos
  • Models
  • Multi-Parameter Optimisation
  • News
  • Ocura
  • Pipeline Pilot Protocols
  • Presentations and Webinars
  • Publications and presentations
  • Scoring Profiles
  • Scripts/Addons
  • StarDrop Hints and Tips
  • StarDrop Modules and Features
  • StarDrop Tutorials
  • Tutorials
  • Upcoming webinar
  • Videos
  • Webinars

Meta

  • Register
  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org

The Optibrium team works at the forefront of decision-analysis and predictive modelling research, developing innovative products that enhance the efficiency and productivity of drug discovery.

enquiries & support

General: [email protected]
StarDrop: [email protected]
Cerella: [email protected]
Press: [email protected]ptibrium.com
Vacancies: [email protected]

  • Follow
  • Follow
further information

View our Privacy Policy

Copyright © 2023 Optibrium, Ltd. All Rights Reserved.
Optibrium™, StarDrop™, Augmented Chemistry®, Cerella™, Asteris™, Ocura™, Glowing Molecule™, WhichP450™, Auto-Modeller™, Nova™, MPO Explorer™ and Card View® are trademarks of Optibrium Ltd. Augmented Chemistry® is registered only in the UK and EU. Card View® is registered only in the United States. Matsy™ is a trademark of NextMove Software Ltd., BIOSTER™ is a trademark of iKem Szolgáltató és Kereskedelmi BT, Derek Nexus™ is a trademark of Lhasa Ltd., Surflex eSim3D is a trademark of BioPharmics LLC, and SeeSAR™ is a trademark of BioSolveIT GmbH. US Patent Numbers 9,224,098 and 9,367,812

Website designed and developed by Identity Creative.

Manage Cookie Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behaviour or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage vendors Read more about these purposes
View preferences
{title} {title} {title}